Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
about
Therapy-Related Myeloid NeoplasmsA meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndromeTherapy-related myeloid neoplasms - what have we learned so far?Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewTherapy-related myeloid neoplasms: pathobiology and clinical characteristicsOutcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.Secondary acute myeloid leukemia after successful treatment for osteosarcoma.Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia.Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclinesIsolated clonal cytogenetic abnormalities after high-dose therapy.Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemiaMyeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivorsMesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.Incidence of acute myeloid leukemia after breast cancer.Therapy-related myeloid neoplasms following treatment with radioiodine.Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?Acute myeloid leukemia following etoposide therapy for EBV-associated hemophagocytic lymphohistiocytosis: a case report and a brief review of the literature.Genetic susceptibility to iatrogenic malignancy.Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.Pharmacogenetics of alkylator-associated acute myeloid leukemia.Therapy-related myeloid neoplasms in 39 Korean patients: a single institution experience.Treatment of acute promyelocytic leukemia for older patients.Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic miceAdvances in the understanding of susceptibility to treatment-related acute myeloid leukaemia.Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia.Therapy-related myeloid leukemia.Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilitySurvival in multiple myeloma patients who develop second malignancies: a population-based cohort studyAcute leukemia as a secondary malignancy in children and adolescents: current findings and issues.
P2860
Q26799786-2129BB24-8DA2-4329-8E9E-F4A687EAF624Q27024786-BE5F38FB-5042-4E79-9964-AD54BD826BD2Q28071318-3B613A3E-9D7F-4655-9492-13E8F90C7440Q28301344-A7178B38-D98C-4EC4-9336-191E71B70C4CQ28386366-51847B0D-8B1E-41A4-8C42-856669164C43Q30620658-830BE4E4-2621-4A69-8C15-566EF5EA6612Q33392211-10AC93C7-1DF5-4B45-B72C-3330B7A177C7Q33435191-87E618B2-217B-43B4-BB6E-393FC41555BEQ33717681-0F797C27-3A10-4241-BD1A-CA083335BD43Q33731691-388222EF-5A7B-463B-9C74-656DAE3023C7Q33822153-BDAF310C-1D1B-4473-8A64-4BC6DDB976EFQ34023749-3545737F-37DE-40C8-9E73-47A1603827FEQ34108964-0A78C4E4-F25D-43DA-8E52-C1E704DECF70Q34227027-A3D33041-7729-4F9B-AAFC-ADB12FCDDC87Q34450715-38927698-A995-413A-9995-83E77A79BA29Q35079660-2D2D0070-E7B5-4E55-B4A1-3B32653E3D2CQ35153662-DADB94C4-7363-4220-83F6-29F08208164EQ35327266-BD541843-6BBE-4D84-BA4F-DD5F47640910Q35553350-6E218F84-437B-4532-9DA7-EE6B2E42BC89Q35640784-5587BF6F-7C3D-41F9-83CF-1DFCC90F137FQ35717790-F9A5233A-DBE8-48BD-80D5-D2118D5B4AF1Q36006426-09135E6C-62F7-482E-A8EF-20057820C8E7Q36090310-F89705EA-8C88-4DD6-A72E-608AF96A3D3EQ36249238-D0031168-D450-4958-B148-9E6C5B009275Q36335336-D69B7CB7-2F62-4422-A7AD-6C1983D90BF5Q36555916-BA8AFBC9-CCB0-4461-B7B1-5C656EF1A40EQ36660513-B6326A44-B501-4E97-8E60-092E3F28BEABQ36672084-7760D863-0F47-425A-B9B9-4C53D0CD6971Q36672691-33F6A3EF-55FB-4898-89B4-F513D21C4DF4Q36709001-05951A62-DA7D-4F94-949B-D3CD717E1684Q36808186-FB85FDBB-82EE-4BB2-B7FF-118D3B33FDF8Q36835079-D457B6D0-4230-4BD6-819F-CF7D878CC397Q36835902-B5053945-2502-46EA-A4C2-AFE83BABD831Q37002149-CC079FAA-F1BA-4932-BAEA-AA423F4AF189Q37009760-7AFEDA71-2B11-43BD-A612-A7F3FA5E575BQ37146052-92DBF170-1A5B-4B2B-A586-0073E0A5A053Q37163850-2A8202A7-599B-4E88-9567-4311433BF900Q37209075-7622BB83-CB47-4C25-85EE-D8989B577E08Q37216305-DF1A22A5-884C-4A10-BA86-4D5AD6FCA04FQ37346340-7CB420D9-170B-4AA9-9D8B-F790E23BAD64
P2860
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Karyotype is an independent pr ...... 091 patients with de novo AML.
@en
Karyotype is an independent pr ...... related acute myeloid leukemia
@nl
type
label
Karyotype is an independent pr ...... 091 patients with de novo AML.
@en
Karyotype is an independent pr ...... related acute myeloid leukemia
@nl
prefLabel
Karyotype is an independent pr ...... 091 patients with de novo AML.
@en
Karyotype is an independent pr ...... related acute myeloid leukemia
@nl
P2093
P2860
P921
P356
P1433
P1476
Karyotype is an independent pr ...... 091 patients with de novo AML.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403187
P577
2004-01-01T00:00:00Z